Tempus AI, Inc. (NASDAQ:TEM) Stock Has Average Target Price of $79.37

Key Points

• Analysts have a consensus “Hold” rating on Tempus AI, with 11 Buy, 10 Hold and 1 Sell recommendations across 22 brokerages; the average 12-month price target is $79.37.
• Several firms raised their targets: BTIG set the highest cited target at $100, Cantor Fitzgerald raised its target to $92, and Needham to $89; Jefferies upgraded the stock to Hold and lifted its target to $70.
• Tempus AI beat quarterly expectations, reporting revenue of $411.54 million, up 23.1% year over year, and EPS of $0.07 versus analysts’ expected loss of $0.09.

Shares of Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) have been given a consensus recommendation of "Hold" by the twenty-two brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $79.37.

TEM has been the subject of a number of research reports. Cantor Fitzgerald upped their target price on shares of Tempus AI from $80.00 to $92.00 and gave the company an "overweight" rating in a report on Tuesday. Jefferies Financial Group upgraded shares of Tempus AI from an "underperform" rating to a "hold" rating and raised their target price for the stock from $35.00 to $70.00 in a research note on Tuesday. Wall Street Zen upgraded Tempus AI from a "sell" rating to a "hold" rating in a research report on Saturday, July 25th. BTIG Research raised their target price on Tempus AI from $80.00 to $100.00 and gave the company a "buy" rating in a report on Tuesday. Finally, Needham & Company LLC boosted their target price on shares of Tempus AI from $75.00 to $89.00 and gave the stock a "buy" rating in a research report on Monday.

Tempus AI Price Performance

Tempus AI stock opened at $70.43 on Friday. The company has a quick ratio of 3.16, a current ratio of 2.61 and a debt-to-equity ratio of 2.70. Tempus AI has a 52-week low of $40.77 and a 52-week high of $89.09. The firm has a market cap of $12.71 billion, a PE ratio of -66.44 and a beta of 3.61. The company's 50 day moving average is $71.21 and its two-hundred day moving average is $57.20.

Tempus AI (NASDAQ:TEM - Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.16. Tempus AI had a negative net margin of 12.54% and a negative return on equity of 47.00%. The business had revenue of $411.54 million during the quarter, compared to analysts' expectations of $409.39 million. During the same period in the previous year, the company earned ($0.46) EPS. The company's revenue for the quarter was up 23.1% on a year-over-year basis. On average, research analysts expect that Tempus AI will post -1.45 EPS for the current fiscal year.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Cantor Fitzgerald maintained its Buy rating, while HC Wainwright and Robert W. Baird were also reported to see strong potential appreciation. These recommendations may support investor confidence. Cantor Fitzgerald maintains Buy rating HC Wainwright forecast Baird forecast
• Positive Sentiment: Recent results were stronger than expected: Tempus reported quarterly revenue of $411.5 million, up 23.1% year over year, and earnings per share of $0.07 versus analysts’ forecast for a loss. The beat provides a favorable business-performance backdrop. Tempus AI earnings beat
• Negative Sentiment: CEO Ryan Fukushima sold 80 shares and director David Epstein sold 370 shares at $74.29. Both trades were executed under pre-arranged Rule 10b5-1 plans, and the small sales leave their substantial holdings largely intact, tempering the potential concern. Director stock sale disclosure

Insider Buying and Selling at Tempus AI

In related news, CEO Ryan Fukushima sold 41,095 shares of the company's stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total value of $2,038,722.95. Following the sale, the chief executive officer owned 562,463 shares of the company's stock, valued at approximately $27,903,789.43. This represents a 6.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Andrew Polovin sold 22,148 shares of Tempus AI stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total value of $1,098,762.28. Following the completion of the sale, the executive vice president directly owned 146,067 shares of the company's stock, valued at approximately $7,246,383.87. This represents a 13.17% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 1,237,227 shares of company stock worth $85,388,983. 24.26% of the stock is currently owned by insiders.

Institutional Trading of Tempus AI

A number of institutional investors and hedge funds have recently modified their holdings of the business. V Square Quantitative Management LLC acquired a new position in shares of Tempus AI during the 3rd quarter worth approximately $27,000. EMC Capital Management acquired a new position in Tempus AI during the 2nd quarter worth approximately $29,000. Whittier Trust Co. lifted its stake in shares of Tempus AI by 190.0% in the 1st quarter. Whittier Trust Co. now owns 870 shares of the company's stock valued at $41,000 after acquiring an additional 570 shares during the last quarter. Ulland Investment Advisors LLC acquired a new position in shares of Tempus AI in the third quarter valued at approximately $41,000. Finally, Heritage Family Offices LLP bought a new stake in Tempus AI in the third quarter valued at approximately $45,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.